title: Claudin-1, -3, -4 and -7 gene expression analyses in canine prostate carcinoma and mammary tissue derived cell lines.
abstract: Claudins (CLDNs) are transmembrane proteins localised in the cell membrane of epithelial cells composing a structural and functional component of the tight junction protein complexes. In canine tumors deregulations of the CLDN expression patterns were described immunohistochemically. Targeting of claudin proteins has further been evaluated to establish novel therapeutic approaches by directed claudin binding. Precondition for the development of claudin targeting approaches in canine cells is the possibility to characterise claudin expression specifically and the availability of claudin positive cell lines. Herein PCR/qPCR assays were established allowing a rapid qualitative and quantitative characterisation of CLDN-1, -3, -4 and -7 gene expression in canine cell lines and tissues. Further commercially available antibodies were used to verify CLDN gene expression on protein level by Western blots. The developed assays were used to analyse six canine cell lines derived from mammary and prostate tissue for their CLDN-1, -3, -4 and -7 expressions. The canine cell line DT08/40 (prostate transitional cell carcinoma) was used for the establishment of specific CLDNs -1, -3, -4 and -7PCR/qPCR. The designed assays were verified by amplicon cloning and sequencing. Gene expressions were verified on protein level by Western blot. Additionally further cell lines were analysed for their CLDN-1, -3, -4 and -7 expression on mRNA and protein level (mammary derived cell lines: MTH53A (non-neoplastic), ZMTH3 (adenoma), MTH52C (carcinoma); prostate derived cell lines: DT08/46 and CT1258 (both adenocarcinoma).The screened cell lines showed expression for the CLDNs as follows: DT08/46 and DT08/40: CLDN-1, -3, -4 and -7 positive; CT1258: CLDN-1, -3, -4 and -7 negative; ZMTH3 and MTH52C: CLDN-1 and -7 positive, CLDN-3 and -4 negative; MTH53A: CLDN-1, -3 and -4 negative, CLDN-7 positive. Western blot analyses reflect the detected CLDN-1, -3, -4 and -7 expressions in the analysed cell lines. The established CLDN-1, -3, -4 and -7 PCR/qPCR assays allow a qualitative and quantitative characterisation of canine CLDN gene expression. Characterisation of CLDN expression in six canine cell lines led to the identification of two canine prostate tissue derived CLDN expressing cell lines. These cell lines serve as candidates for further research on CLDN-based functional and therapeutic approaches.
authors.forename: S C
authors.initials: SC
authors.lastname: Hammer
authors.forename: S
authors.initials: S
authors.lastname: Nagel
authors.forename: J
authors.initials: J
authors.lastname: Junginger
authors.forename: M
authors.initials: M
authors.lastname: Hewicker-Trautwein
authors.forename: S
authors.initials: S
authors.lastname: Wagner
authors.forename: A
authors.initials: A
authors.lastname: Heisterkamp
authors.forename: A
authors.initials: A
authors.lastname: Ngezahayo
authors.forename: I
authors.initials: I
authors.lastname: Nolte
authors.forename: H
authors.initials: H
authors.lastname: Murua Escobar
mesh_terms: D000818:Animals; D014408:Biomarkers, Tumor / Q000378:metabolism; D045744:Cell Line, Tumor; D062445:Claudin-1 / Q000096:biosynthesis* / Q000235:genetics; D062465:Claudin-3 / Q000096:biosynthesis* / Q000235:genetics; D062506:Claudin-4 / Q000096:biosynthesis* / Q000235:genetics; D004285:Dogs; D015972:Gene Expression Regulation, Neoplastic; D008297:Male; D016133:Polymerase Chain Reaction; D011467:Prostate / Q000473:pathology*; D011471:Prostatic Neoplasms / Q000235:genetics / Q000473:pathology*; D062725:Tight Junction Proteins / Q000235:genetics
chemical_list: D014408:Biomarkers, Tumor; D062445:Claudin-1; D062465:Claudin-3; D062506:Claudin-4; D062725:Tight Junction Proteins
keywords: claudins; mammary cancer; marker expression.; prostate cancer